Home › US companies › Icon
Icon
ICLR · Nasdaq · Services-Commercial Physical & Biological Research
Insider buys (12 months)
0
Insider sales (12 months)
$3.5M
8-K reports (12 months)
0
Tracked investors holding
0
At a glance
Icon reported 2025 revenue of $8.25B, up 0.8% from $8.19B in 2024. Over 4 years since 2021 ($5.48B), that is growth of about 10.8% a year. Operating margin was 5.4%, down from 6.9% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 8 insiders reported 0 open-market purchases and 9 sales ($3.5M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $876K by Director Ronan Martin Murphy on Sep 18, 2026.
Annual results
2021
Revenue $5.48B
Op. $378.5M
2022
Revenue $7.74B
Op. $795.2M
2023
Revenue $8.05B
Op. $904.7M
2024
Revenue $8.19B
Op. $1.03B
2025
Revenue $8.25B
Op. $442.8M
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $153.2M | $505.3M | $554.2M | $739.1M | $229.3M |
| Diluted EPS | $2.25 | $6.13 | $6.70 | $8.90 | $2.90 |
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined